Transdermal Opioids for Cancer Pain
Author Information
Author(s): Skaer Tracy L
Primary Institution: College of Pharmacy, Washington State University
Hypothesis
Can transdermal opioids provide effective pain management for cancer patients?
Conclusion
Transdermal formulations of fentanyl and buprenorphine are effective for managing moderate to severe cancer pain, but dosing must be individualized to avoid undertreatment.
Supporting Evidence
- Transdermal fentanyl is effective and well tolerated for cancer pain.
- Many cancer patients are prescribed subtherapeutic doses of pain medications.
- A more aggressive dosing algorithm is recommended for transdermal fentanyl.
Takeaway
This study shows that special patches can help cancer patients manage their pain better, but doctors need to be careful about how much they give.
Methodology
The study involved a review of literature and clinical experience regarding the use of transdermal opioids in cancer pain management.
Potential Biases
Potential bias in the selection of studies reviewed and the interpretation of results.
Limitations
The study may not account for all individual patient factors affecting pain management.
Participant Demographics
The study included cancer patients, with a focus on those experiencing moderate to severe pain.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website